Cyclophosphamide

Generic Name: Cyclophosphamide

Brand Names: Procytox

Drug Type: Small Molecule

Chemical Formula: C_₇H_₁₅Cl_₂N_₂O_₂P

CAS Number: 50-18-0

Unique Ingredient Identifier: 6UXW23996M

Background: Precursor of an alkylating nitrogen mustard antineoplastic and immunosuppressive agent that must be activated in the liver to form the active aldophosphamide. It has been used in the treatment of lymphoma and leukemia. Its side effect, alopecia, has been used for defleecing sheep. Cyclophosphamide may also cause sterility, birth defects, mutations, and cancer.

Indication: Cyclophosphamide is indicated for the treatment of malignant lymphomas, multiple myeloma, leukemias, mycosis fungoides (advanced disease), neuroblastoma (disseminated disease), adenocarcinoma of the ovary, retinoblastoma, and carcinoma of the breast. It is also indicated for the treatment of biopsy-proven minimal change nephrotic syndrome in pediatric patients.

Associated Conditions: Acute Lymphoblastic Leukaemias (ALL), Acute Myeloid Leukemia, Acute monocytic leukemia, Adenocarcinoma of the Ovaries, Breast Cancer, Burkitt Lymphoma, Chronic Lymphocytic Leukemia, Chronic Myelogenous Leukemia (CML), Hodgkins Disease (HD), Lung Cancer, Lupus, Lymphocytic Lymphomas, Lymphoma, Multiple Myeloma (MM), Multiple Sclerosis, Nephrotic syndrome with lesion of minimal change glomerulonephritis, Non-Hodgkin's Lymphoma (NHL), Retinoblastoma, Advanced Alibert-Bazin syndrome, Chronic Granulocytic Leukemias, Disseminated Neuroblastoma (NB), Histiocytic lymphoma, Mixed-cell type lymphoma

Associated Therapies: -

Clinical Trials

Neoadjuvant Study Chemotherapy vs Letrozole + Abemaciclib in HR+/HER2- High/Intermediate Risk Breast Cancer Patients

Phase 2

Active, not recruiting

Conditions: Early Breast Cancer

Interventions: Drug: Doxorubicin
Drug: Letrozole
Drug: Cyclophosphamide
Drug: Abemaciclib
Drug: Taxane
Drug: LHRH Analogue

First Posted Date: 2020-03-03

Last Posted Date: 2024-07-29

Lead Sponsor: Spanish Breast Cancer Research Group

Target Recruit Count: 200

Registration Number: NCT04293393

Locations: 🇪🇸
Hospital Universitario de Burgos, Burgos, Spain
🇪🇸
Hospital Universitario Ramón y Cajal, Madrid, Spain
🇪🇸
Hospital General Universitario de Alicante, Alicante, Spain

and more 24 locations

Neoadjuvant Chemotherapy With Pyrotinib, Epirubicin and Cyclophosphamide Followed by Taxanes and Trastuzumab for HER-2+ Breast Cancer

Phase 2

Conditions: Breast Cancer

Interventions: Drug: Pyrotinib
Drug: Epirubicin
Drug: Cyclophosphamide
Drug: Taxanes
Biological: Trastuzumab

First Posted Date: 2020-03-02

Last Posted Date: 2020-03-02

Lead Sponsor: Hebei Medical University Fourth Hospital

Target Recruit Count: 280

Registration Number: NCT04290793

A Study to Compare the Efficacy and Safety of a Combined Regimen of Venetoclax and Obinutuzumab Versus Fludarabine, Cyclophosphamide, and Rituximab (FCR)/ Bendamustine And Rituximab (BR) in FIT Patients With Previously Untreated Chronic Lymphocytic Leukemia (CLL) Without DEL (17P) or TP53 Mutation

Phase 3

Active, not recruiting

Conditions: Chronic Lymphocytic Leukemia (CLL)

Interventions: Drug: Obinutuzumab
Drug: Fludarabine
Drug: Venetoclax
Drug: Cyclophosphamide
Drug: Rituximab
Drug: Bendamustine

First Posted Date: 2020-02-26

Last Posted Date: 2024-10-16

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 166

Registration Number: NCT04285567

Locations: 🇫🇷
CHU de Caen, Institut d'Hématologie de Basse-Normandie, Caen, France
🇫🇷
Hopital Robert Debre; Hematologie Clinique, Reims, France
🇺🇸
Oncology & Hematolgy Associates of SW Va Inc. - Roanoke, Roanoke, Virginia, United States

and more 45 locations

CD34+ Enriched Transplants From HLA-Compatible Patients With Hematologic Malignancies

Phase 2

Withdrawn

Conditions: Hematologic Malignancy
Hematologic Diseases
Acute Lymphoblastic Leukemia
Acute Myeloid Leukemia
Chronic Lymphocytic Leukemia
Chronic Myelogenous Leukemia

Interventions: Device: CliniMACS
Procedure: Bone Marrow Transplant
Drug: Hyperfractionated Total Body Irradiation
Drug: Busulfan
Drug: Thiotepa
Drug: Melphalan
Drug: Cyclophosphamide
Drug: Fludarabine

First Posted Date: 2020-02-24

Last Posted Date: 2022-09-27

Lead Sponsor: Baptist Health South Florida

Registration Number: NCT04282174

Locations: 🇺🇸
Miami Cancer Institute at Baptist Health, Inc., Miami, Florida, United States

Total Marrow and Lymphoid Irradiation as Conditioning Regimen Before Hematopoietic Cell Transplantation in Patients With Myelodysplastic Syndrome or Acute Leukemia

Phase 2

Recruiting

Conditions: Myelodysplastic Syndrome
Acute Lymphoblastic Leukemia
Acute Myeloid Leukemia
High Risk Myelodysplastic Syndrome

Interventions: Drug: Cyclophosphamide
Drug: Fludarabine
Drug: Fludarabine Phosphate
Biological: Granulocyte Colony-Stimulating Factor
Procedure: Hematopoietic Cell Transplantation
Procedure: Intensity-Modulated Radiation Therapy
Drug: Mycophenolate Mofetil
Drug: Tacrolimus

First Posted Date: 2020-02-10

Last Posted Date: 2024-03-06

Lead Sponsor: City of Hope Medical Center

Target Recruit Count: 70

Registration Number: NCT04262843

Locations: 🇺🇸
City of Hope Medical Center, Duarte, California, United States

FT596 as a Monotherapy and in Combination With Anti-CD20 Monoclonal Antibodies

Phase 1

Terminated

Conditions: Lymphoma, B-Cell
Chronic Lymphocytic Leukemia

Interventions: Drug: FT596
Drug: Cyclophosphamide
Drug: Fludarabine
Drug: Bendamustine
Drug: Rituximab
Drug: Obinutuzumab

First Posted Date: 2020-01-29

Last Posted Date: 2023-10-26

Lead Sponsor: Fate Therapeutics

Target Recruit Count: 98

Registration Number: NCT04245722

Locations: 🇺🇸
The University of Chicago, Chicago, Illinois, United States
🇺🇸
University of Minnesota Masonic Cancer Center, Minneapolis, Minnesota, United States
🇺🇸
MD Anderson Cancer Center, Houston, Texas, United States

and more 6 locations

A Study to Evaluate the Efficacy and Safety of JCAR017 in Adult Subjects With Relapsed or Refractory Indolent B-cell Non-Hodgkin Lymphoma (NHL)

Phase 2

Recruiting

Conditions: Lymphoma, Non-Hodgkin

Interventions: Drug: Fludarabine
Drug: Cyclophosphamide
Drug: JCAR017

First Posted Date: 2020-01-29

Last Posted Date: 2024-12-10

Lead Sponsor: Celgene

Target Recruit Count: 276

Registration Number: NCT04245839

Locations: 🇺🇸
University of Maryland - Greenebaum Comprehensive Cancer Center, Baltimore, Maryland, United States
🇺🇸
Local Institution - 111, Santa Monica, California, United States
🇺🇸
University Of Colorado Cancer Center, Aurora, Colorado, United States

and more 54 locations

Cemiplimab in High Risk or Locally Advanced Hormone Receptor Positive HER2 Negative or Triple-Negative Breast Cancer

Phase 2

Recruiting

Conditions: Invasive Breast Cancer

Interventions: Drug: Cemiplimab
Drug: Paclitaxel
Drug: Carboplatin (not mandatory)
Drug: Doxorubicin
Drug: Cyclophosphamide

First Posted Date: 2020-01-28

Last Posted Date: 2024-02-06

Lead Sponsor: Medical College of Wisconsin

Target Recruit Count: 36

Registration Number: NCT04243616

Locations: 🇺🇸
Froedtert Hospital & Medical College of Wisconsin, Milwaukee, Wisconsin, United States

Bortezomib, Isatuximab, Cyclophosphamide and Dexamethasone Induction in Transplant-Eligible Multiple Myeloma Patients

Phase 2

Recruiting

Conditions: Multiple Myeloma

Interventions: Drug: Bortezomib
Drug: Isatuximab
Drug: Cyclophosphamide
Drug: Dexamethasone

First Posted Date: 2020-01-27

Last Posted Date: 2024-01-09

Lead Sponsor: Medical College of Wisconsin

Target Recruit Count: 41

Registration Number: NCT04240054

Locations: 🇺🇸
Rush University Medical Center, Chicago, Illinois, United States
🇺🇸
Froedtert Hospital & the Medical College of Wisconsin, Milwaukee, Wisconsin, United States

9-ING-41 in Pediatric Patients with Refractory Malignancies.

Phase 1

Recruiting

Conditions: Cancer Pediatric
Pediatric Cancer
Pediatric Brain Tumor
Refractory Cancer
Refractory Tumor
Pediatric Meningioma
Neuroblastoma
Neuroblastoma Recurrent
Refractory Neoplasm
Pediatric Lymphoma

Interventions: Drug: 9-ING-41
Drug: Irinotecan
Drug: Cyclophosphamide
Drug: Temozolomide
Drug: Topotecan

First Posted Date: 2020-01-23

Last Posted Date: 2024-11-08

Lead Sponsor: Actuate Therapeutics Inc.

Target Recruit Count: 68

Registration Number: NCT04239092

Locations: 🇺🇸
University of California, San Francisco, San Francisco, California, United States
🇺🇸
Children's Hospital Colorado, Aurora, Colorado, United States
🇺🇸
University of Chicago, Chicago, Illinois, United States

and more 6 locations

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy